Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
48
PRCT Quote, Financials, Valuation and Earnings
Last price:
$52.53
Seasonality move
:
16.71%
Day range:
$48.43 - $52.57
52-week range:
$47.04 - $103.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.19x
P/B ratio:
7.39x
Volume:
2M
Avg. volume:
1.1M
1-year change:
0.4%
Market cap:
$2.9B
Revenue:
$224.5M
EPS (TTM):
-$1.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$65.4M | -$0.49 | 42.33% | -21.43% | $77.00 |
|
BSX
Boston Scientific
|
$4.9B | $0.72 | 18.76% | 229.31% | $116.12 |
|
CATX
Perspective Therapeutics
|
$123.2K | -$0.31 | -- | -35.77% | $14.39 |
|
RXST
RxSight
|
$40.2M | -$0.03 | 34.7% | -73.88% | $24.36 |
|
VNRX
VolitionRX
|
$1.2M | -$0.04 | 197.5% | -46.88% | $2.92 |
|
XTNT
Xtant Medical Holdings
|
$32.4M | -$0.01 | 9.96% | -33.33% | $1.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$52.49 | $77.00 | $2.9B | -- | $0.00 | 0% | 11.19x |
|
BSX
Boston Scientific
|
$101.90 | $116.12 | $150.7B | 74.38x | $0.00 | 0% | 8.64x |
|
CATX
Perspective Therapeutics
|
$2.39 | $14.39 | $177M | -- | $0.00 | 0% | 15.47x |
|
RXST
RxSight
|
$14.95 | $24.36 | $605.3M | -- | $0.00 | 0% | 4.15x |
|
VNRX
VolitionRX
|
$0.49 | $2.92 | $47.9M | -- | $0.00 | 0% | 34.16x |
|
XTNT
Xtant Medical Holdings
|
$0.51 | $1.75 | $70.9M | -- | $0.00 | 0% | 0.58x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
12.09% | 1.542 | 1.68% | 7.60x |
|
BSX
Boston Scientific
|
32.79% | 0.797 | -- | 0.46x |
|
CATX
Perspective Therapeutics
|
-- | -2.375 | -- | -- |
|
RXST
RxSight
|
-- | 1.443 | -- | 10.33x |
|
VNRX
VolitionRX
|
-28.76% | 0.042 | 8.83% | 0.19x |
|
XTNT
Xtant Medical Holdings
|
44.29% | 0.123 | 55.45% | 0.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRCT
PROCEPT BioRobotics
|
$44.2M | -$27.4M | -24.95% | -29.12% | -34.5% | -$33.6M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.43% | 8.96% | 19.02% | $1.2B |
|
CATX
Perspective Therapeutics
|
-- | -$20.9M | -- | -- | -- | -$41.2M |
|
RXST
RxSight
|
$28.8M | -$8.6M | -11.86% | -11.86% | -14.72% | -$5.1M |
|
VNRX
VolitionRX
|
-- | -$5.8M | -- | -- | -1217.88% | -$5.5M |
|
XTNT
Xtant Medical Holdings
|
$16M | -$1.9M | -21.41% | -35.34% | -6.38% | -$7K |
PROCEPT BioRobotics vs. Competitors
-
Which has Higher Returns PRCT or BSX?
Boston Scientific has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of 14.45%. PROCEPT BioRobotics's return on equity of -29.12% beat Boston Scientific's return on equity of 8.96%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M BSXBoston Scientific68.84% $0.45 $32.6B -
What do Analysts Say About PRCT or BSX?
PROCEPT BioRobotics has a consensus price target of $77.00, signalling upside risk potential of 46.7%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 13.96%. Given that PROCEPT BioRobotics has higher upside potential than Boston Scientific, analysts believe PROCEPT BioRobotics is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 BSXBoston Scientific23 4 0 -
Is PRCT or BSX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.
-
Which is a Better Dividend Stock PRCT or BSX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or BSX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are smaller than Boston Scientific quarterly revenues of $4.7B. PROCEPT BioRobotics's net income of -$24.7M is lower than Boston Scientific's net income of $674M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.19x versus 8.64x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.19x -- $69.2M -$24.7M BSXBoston Scientific8.64x 74.38x $4.7B $674M
-
Which has Higher Returns PRCT or CATX?
Perspective Therapeutics has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of --. PROCEPT BioRobotics's return on equity of -29.12% beat Perspective Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M CATXPerspective Therapeutics-- -$0.61 -- -
What do Analysts Say About PRCT or CATX?
PROCEPT BioRobotics has a consensus price target of $77.00, signalling upside risk potential of 46.7%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Perspective Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Perspective Therapeutics is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 CATXPerspective Therapeutics10 1 0 -
Is PRCT or CATX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.
-
Which is a Better Dividend Stock PRCT or CATX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or CATX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Perspective Therapeutics quarterly revenues of --. PROCEPT BioRobotics's net income of -$24.7M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.19x versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.19x -- $69.2M -$24.7M CATXPerspective Therapeutics15.47x -- -- -$40.2M
-
Which has Higher Returns PRCT or RXST?
RxSight has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -14.77%. PROCEPT BioRobotics's return on equity of -29.12% beat RxSight's return on equity of -11.86%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M RXSTRxSight71.59% -$0.15 $281.2M -
What do Analysts Say About PRCT or RXST?
PROCEPT BioRobotics has a consensus price target of $77.00, signalling upside risk potential of 46.7%. On the other hand RxSight has an analysts' consensus of $24.36 which suggests that it could grow by 62.97%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 RXSTRxSight3 4 0 -
Is PRCT or RXST More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRCT or RXST?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or RXST?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than RxSight quarterly revenues of $40.2M. PROCEPT BioRobotics's net income of -$24.7M is lower than RxSight's net income of -$5.9M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.19x versus 4.15x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.19x -- $69.2M -$24.7M RXSTRxSight4.15x -- $40.2M -$5.9M
-
Which has Higher Returns PRCT or VNRX?
VolitionRX has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -1226.82%. PROCEPT BioRobotics's return on equity of -29.12% beat VolitionRX's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M VNRXVolitionRX-- -$0.07 -$17.8M -
What do Analysts Say About PRCT or VNRX?
PROCEPT BioRobotics has a consensus price target of $77.00, signalling upside risk potential of 46.7%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 500.41%. Given that VolitionRX has higher upside potential than PROCEPT BioRobotics, analysts believe VolitionRX is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 VNRXVolitionRX2 1 0 -
Is PRCT or VNRX More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.
-
Which is a Better Dividend Stock PRCT or VNRX?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or VNRX?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than VolitionRX quarterly revenues of $474.5K. PROCEPT BioRobotics's net income of -$24.7M is lower than VolitionRX's net income of -$5.8M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.19x versus 34.16x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.19x -- $69.2M -$24.7M VNRXVolitionRX34.16x -- $474.5K -$5.8M
-
Which has Higher Returns PRCT or XTNT?
Xtant Medical Holdings has a net margin of -35.77% compared to PROCEPT BioRobotics's net margin of -10.04%. PROCEPT BioRobotics's return on equity of -29.12% beat Xtant Medical Holdings's return on equity of -35.34%.
Company Gross Margin Earnings Per Share Invested Capital PRCTPROCEPT BioRobotics63.85% -$0.45 $442.7M XTNTXtant Medical Holdings50.85% -$0.02 $77.1M -
What do Analysts Say About PRCT or XTNT?
PROCEPT BioRobotics has a consensus price target of $77.00, signalling upside risk potential of 46.7%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 243.14%. Given that Xtant Medical Holdings has higher upside potential than PROCEPT BioRobotics, analysts believe Xtant Medical Holdings is more attractive than PROCEPT BioRobotics.
Company Buy Ratings Hold Ratings Sell Ratings PRCTPROCEPT BioRobotics6 2 0 XTNTXtant Medical Holdings2 0 0 -
Is PRCT or XTNT More Risky?
PROCEPT BioRobotics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.
-
Which is a Better Dividend Stock PRCT or XTNT?
PROCEPT BioRobotics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PROCEPT BioRobotics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRCT or XTNT?
PROCEPT BioRobotics quarterly revenues are $69.2M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. PROCEPT BioRobotics's net income of -$24.7M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, PROCEPT BioRobotics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PROCEPT BioRobotics is 11.19x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRCTPROCEPT BioRobotics11.19x -- $69.2M -$24.7M XTNTXtant Medical Holdings0.58x -- $31.5M -$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
